Abstract

Reperfusion injury following acute myocardial infarction is associated with significant morbidity. Activation of neuronal or non-neuronal cholinergic pathways in the heart has been shown to reduce ischemic injury, and this effect has been attributed primarily to muscarinic acetylcholine receptors. In contrast, the role of nicotinic receptors, specifically α-7 subtype (α7nAChR), in the myocardium remains unknown, which offers an opportunity to potentially repurpose several agonists/modulators that are currently under development for neurologic indications. Treatment of ex vivo and in vivo rat models of cardiac ischemia/reperfusion (I/R) with a selective α7nAChR agonist (GTS21) showed significant increases in left ventricular developing pressure and rates of pressure development, without effects on heart rate. These positive functional effects were blocked by co-administration with methyllycaconitine (MLA), a selective antagonist of α7nAChRs. In vivo, delivery of GTS21 at the initiation of reperfusion reduced infarct size by 42% (p < 0.01) and decreased tissue reactive oxygen species (ROS) by 62% (p < 0.01). Flow cytometry of MitoTracker Red-stained mitochondria showed that mitochondrial membrane potential was normalized in mitochondria isolated from GTS21-treated compared with untreated I/R hearts. Intracellular adenosine triphosphate (ATP) concentration in cultured cardiomyocytes exposed to hypoxia/reoxygenation was reduced (p < 0.001), but significantly increased to normoxic levels with GTS21 treatment, which was abrogated by MLA pretreatment. Activation of stress-activated kinases JNK and p38MAPK was significantly reduced by GTS21 in I/R. We conclude that targeting myocardial α7nAChRs in I/R may provide therapeutic benefit by improving cardiac contractile function through a mechanism that preserves mitochondrial membrane potential, maintains intracellular ATP and reduces ROS generation, thus limiting infarct size.

Highlights

  • Cardiac contractility, pacemaker activity and conduction are controlled by the autonomic nervous system, with catecholaminergic and cholinergic signals originating from sympathetic and parasympathetic neural pathways

  • Assuming that contractile function of all isolated perfused hearts deteriorates with perfusion time, the statistical analysis that was used for these studies utilized Left ventricular (LV) pressures recorded from 0 to 30 min reperfusion

  • The optimum treatment dose of GTS21 was determined empirically by measuring LV function through a concentration range from 10-7 to 10-9 M and was the dose that produced the highest recovery of left ventricular developed pressure (LVDP) during reperfusion

Read more

Summary

Introduction

Pacemaker activity and conduction are controlled by the autonomic nervous system, with catecholaminergic and cholinergic signals originating from sympathetic and parasympathetic neural pathways. Experimental studies aimed at reducing cholinergic neural activity using mice deficient in muscarinic-­acetylcholine receptors (AChR) or vesicular acetylcholine transporters (VAChT) have clearly shown that the parasympathetic nervous system has a protective role in maintaining cardiac function [24,25]. Vagus nerve stimulation in animal studies and in patients with heart failure has shown improvement in cardiac function, suggesting that cholinergic-pathway activation may provide therapeutic benefit (5,18,45,53,). Other studies using drugs to augment the parasympathetic nervous system or influence vagal tone, including acetylcholinesterase inhibitors such as donepezil or pyridostigmine, show evidence of improved ventricular remodeling and autonomic function in animal models of heart failure or after myocardial infarction [13, 26,32, 37,42]. Studies of patients treated with these drugs for Alzheimer’s dementia have reported reduced ­adverse cardiac events, including ­myocardial infarction and death [31]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call